Genmab A/S (NASDAQ:GMAB) Upgraded at Truist Financial

Truist Financial upgraded shares of Genmab A/S (NASDAQ:GMAB) to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

GMAB has been the subject of a number of other research reports. Wolfe Research began coverage on Genmab A/S in a research report on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective for the company. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Finally, Morgan Stanley started coverage on shares of Genmab A/S in a report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.36.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $26.11 on Monday. Genmab A/S has a one year low of $18.89 and a one year high of $35.43. The business’s fifty day moving average price is $27.48 and its two-hundred day moving average price is $30.09. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The stock has a market cap of $16.78 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 1.20 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. On average, analysts forecast that Genmab A/S will post 1.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Integrated Advisors Network LLC acquired a new position in Genmab A/S in the first quarter valued at $205,000. AdvisorShares Investments LLC boosted its holdings in Genmab A/S by 2.2% in the first quarter. AdvisorShares Investments LLC now owns 30,853 shares of the company’s stock valued at $828,000 after acquiring an additional 653 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Genmab A/S in the first quarter valued at $34,000. QRG Capital Management Inc. boosted its holdings in Genmab A/S by 7.4% in the first quarter. QRG Capital Management Inc. now owns 65,822 shares of the company’s stock valued at $1,766,000 after acquiring an additional 4,561 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Genmab A/S in the first quarter valued at $1,198,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.